Exciting Therapies on the Horizon for Atopic Dermatitis, with Raj Chovatiya, MD, PhD

Author(s):

Chovatiya discussed his talk at the 2025 AAAAI/WAO Joint Congress.

The atopic dermatitis field has seen lots of innovation in recent years with novel therapies and mechanisms, and this is only continuing.

Raj Chovatiya, MD, PhD, Clinical Associate Professor of Medicine at Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago, Illinois, gave a talk at the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress, February 28-March 3, in San Diego, California, focusing on the continuing innovation in the field entitled “Novel Pipeline Therapies for Atopic Dermatitis: Beyond IL-13 and JAKi”.

HCPLive® spoke with Chovatiya to learn more about his perspective on the progress the field has seen in recent years, and where the focus of research has turned to. A big priority for the field right now is tweaking and optimizing current treatment mechanisms and strategies to achieve greater efficacy and longer remission, Chovatiya said. He also shared that the field is really starting to think about achieving “remission” in patients with atopic dermatitis, although definitions still vary about what remission may mean for patients.

“We laugh about this idea of the “R-word” in atopic dermatitis - remission. Everybody wants to talk about it, thinks they have a definition for it, and thinks they're going to get there. I would probably take a much more cautious approach, saying that it's possible we might, if we all agree on what it is, but I think that that's what a lot of our newer therapies and targets are really trying to go after,” Chovatiya told HCPLive.

Chovatiya has reported serving as an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc, Regeneron, RAPT, Sanofi, Sitryx, and UCB.